Cargando…
Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation
Here, we report the case of a patient, diagnosed with BRAF(V600E)-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient’s decision...
Autores principales: | Brugnara, Sonia, Sicher, Mariacristina, Bonandini, Elena Maria, Donner, Davide, Chierichetti, Franca, Barbareschi, Mattia, Girardelli, Carlo Renè, Caffo, Orazio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819728/ https://www.ncbi.nlm.nih.gov/pubmed/29483930 http://dx.doi.org/10.7573/dic.212515 |
Ejemplares similares
-
Onset of vitiligo following targeted therapy for BRAF(V600E)-mutated melanoma: case report
por: Brugnara, Sonia, et al.
Publicado: (2019) -
Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020) -
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2021) -
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023) -
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)